关于炎症性皮肤病的人工智能:我们现在在哪里,我们要去哪里?
Dimitri Luz F Silva1, Rafael Rubinho2, Ariany Denofre3
1Department of Dermatology, Universidade de Santo Amaro, São Paulo, SP, Brazil; Discipline of Dermatology, Universidade de Campinas, Campinas, SP, Brazil.
Anais brasileiros de dermatologia
|July 19, 2025
概括
人工智能 (AI) 在诊断炎症性皮肤疾病方面表现有前途,超越了最初关注皮肤癌的范围. 这篇评论强调了人工智能.
科学领域:
- 皮肤病学 皮肤病学
- 人工智能的人工智能
- 医学成像分析 医学成像分析
背景情况:
- 人工智能 (AI) 的诊断准确度与皮肤病变的皮肤科医生相美.
- 皮肤病学当前的人工智能发展主要针对由于高患病率和发病率而导致的瘤性疾病.
- 焦点正在转向探索AI在其他皮肤病领域的潜力.
研究的目的:
- 审查和描述人工智能在炎症性皮肤病领域的新兴应用.
- 巩固当前关于人工智能在管理非新形成性皮肤疾病中的作用的研究.
主要方法:
- 在Medline和Lilacs数据库中进行了系统的文献搜索.
- 在2013年至2023年间发表的文章使用特定的包含和排除标准进行了选.
- 从19篇选定的文章中提取了信息,以综合审查结果.
主要成果:
- 早期的人工智能皮肤病学研究集中在诸如黑色素瘤之类的瘤上,实现了高诊断准确度.
- 最近的研究越来越多地探讨了AI在炎症性皮肤病中的应用,包括牛皮,补充性水炎和亚托邦性皮肤炎.
- 人工智能工具正在开发,以协助客观评估,例如计算牛皮区域和严重性指数 (PASI) 评分.
结论:
- 这项研究是一项文献综述,承认了AI对炎症性皮肤病的创新性质和有限的发表研究.
- 尽管存在局限性,但皮肤病学对人工智能的兴趣日益增长,未来进步的潜力显著.
- 人工智能即将成为一种有价值的工具,以支持皮肤科医生在临床实践中.
相关概念视频
01:23Skin Diseases and Disorders
4.2K
Skin is the first line of defense and encounters a variety of microbes. Some pathogenic strains are often the cause of a broad range of infections of the skin and other body systems. These conditions can affect people of all ages and may have different causes, including genetic factors, infections, autoimmune reactions, environmental factors, and lifestyle choices.
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
4.2K
01:24T Cell Types and Functions
1.4K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.4K
01:19Clinical Applications of Epidermal Stem Cells
2.8K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
2.8K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
236
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
236
01:29Inflammatory Bowel Disease IV: Pharmacological Management
196
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
196
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
271
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
271